327 related articles for article (PubMed ID: 29155143)
1. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
3. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
4. Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters.
Dong B; Young M; Liu X; Singh AB; Liu J
J Lipid Res; 2017 Feb; 58(2):350-363. PubMed ID: 27940481
[TBL] [Abstract][Full Text] [Related]
5. Diet-induced dyslipidemia impairs reverse cholesterol transport in hamsters.
Tréguier M; Briand F; Boubacar A; André A; Magot T; Nguyen P; Krempf M; Sulpice T; Ouguerram K
Eur J Clin Invest; 2011 Sep; 41(9):921-8. PubMed ID: 21299553
[TBL] [Abstract][Full Text] [Related]
6. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
8. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
9. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
10. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters.
Wang Y; Zhu Y; Niu J; Deng Q; Guo S; Jiang H; Peng Z; Xue Y; Peng H; Xuan L; Pan G
Toxicol Appl Pharmacol; 2020 Oct; 404():115169. PubMed ID: 32738331
[TBL] [Abstract][Full Text] [Related]
11. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
13. Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet.
Svop Jensen V; Fledelius C; Max Wulff E; Lykkesfeldt J; Hvid H
Nutrients; 2021 Feb; 13(2):. PubMed ID: 33673227
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
15. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Zhao J; Li B; Zhang K; Zhu Z
Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
17. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.
Pencek R; Marmon T; Roth JD; Liberman A; Hooshmand-Rad R; Young MA
Diabetes Obes Metab; 2016 Sep; 18(9):936-40. PubMed ID: 27109453
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
19. Electronegative LDL is linked to high-fat, high-cholesterol diet-induced nonalcoholic steatohepatitis in hamsters.
Lai YS; Yang TC; Chang PY; Chang SF; Ho SL; Chen HL; Lu SC
J Nutr Biochem; 2016 Apr; 30():44-52. PubMed ID: 27012620
[TBL] [Abstract][Full Text] [Related]
20. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease.
Christensen CU; Glavind E; Thomsen KL; Kim YO; Heebøll S; Schuppan D; Hamilton-Dutoit S; Würtz Heegaard C; Grønbæk H
PLoS One; 2018; 13(3):e0192728. PubMed ID: 29522534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
